YELOSUPPRESSION is often a dose-limiting side effect of chemotherapeutic drugs in the treatment of cancer. Thus, strategies to prevent myelosuppression from chemotherapy could lead to reduced side effects, dose intensification, and perhaps improved survival. In this regard, the multidrug resistance (MDR1) gene product is a 170-kD transmembrane glycoprotein (gp 170) whose expression in mammalian cells is associated with increased drug resistance.' GP 170 is an adenosine triphosphate (ATP)-dependent drug efflux pump that prevents the accumulation of many natural substances and anticancer drugs including the anthracyclines, vinca alkaloids, etoposide, and paclitaxel.' The enforced expression of the human MDRl gene in bone marrow (BM) cells of transgenic mice protected these mice from the myelosuppressive effects of chemotherapeutic agents in vivo.3 Furthermore, BM cells from MDRl transgenic mice transplanted into lethally irradiated mice, protected the recipient mice from chemotherapy-induced myelos~ppression.~ Thus, transfer of the MDRl gene to BM stem cells is an attractive gene therapy approach to confer drug resistance to hematopoietic cells and could prevent the neutropenia and thrombocytopenia associated with chemotherapy.' In this regard, previous studies reported that transplantation of murine BM cells that were infected with MDRl containing retroviruses into lethally irradiated recipients resulted in consistently very low levels MDRl expression in developing hematopoietic cells 6 months after transplantation.s.6 However, treatment of these mice with paclitaxel in vivo resulted in an enrichment of hematopoietic cells expressing MDRl that were resistant to subsequent treatment with paclitaxel.s.6 Thus, MDRl expression is accompanied by functional drug resistance in murine in vivo models.
YELOSUPPRESSION is often a dose-limiting side effect of chemotherapeutic drugs in the treatment of cancer. Thus, strategies to prevent myelosuppression from chemotherapy could lead to reduced side effects, dose intensification, and perhaps improved survival. In this regard, the multidrug resistance (MDR1) gene product is a 170-kD transmembrane glycoprotein (gp 170) whose expression in mammalian cells is associated with increased drug resistance.' GP 170 is an adenosine triphosphate (ATP)-dependent drug efflux pump that prevents the accumulation of many natural substances and anticancer drugs including the anthracyclines, vinca alkaloids, etoposide, and paclitaxel. ' The enforced expression of the human MDRl gene in bone marrow (BM) cells of transgenic mice protected these mice from the myelosuppressive effects of chemotherapeutic agents in vivo.3 Furthermore, BM cells from MDRl transgenic mice transplanted into lethally irradiated mice, protected the recipient mice from chemotherapy-induced myelos~ppression.~ Thus, transfer of the MDRl gene to BM stem cells is an attractive gene therapy approach to confer drug resistance to hematopoietic cells and could prevent the neutropenia and thrombocytopenia associated with chemotherapy.' In this regard, previous studies reported that transplantation of murine BM cells that were infected with MDRl containing retroviruses into lethally irradiated recipients resulted in consistently very low levels MDRl expression in developing hematopoietic cells 6 months after transplantation.s.6 However, treatment of these mice with paclitaxel in vivo resulted in an enrichment of hematopoietic cells expressing MDRl that were resistant to subsequent treatment with paclitaxel.s.6 Thus, MDRl expression is accompanied by functional drug resistance in murine in vivo models.
Retroviral-mediated gene transfer of the MDRl gene has also been reported using purified human CD34+ progenitor cells.' When CD34+ cells were cultured in cytokines for 6 days after they were infected with MDRl-containing retroviruses, up to 11% of the resulting progeny expressed MDRl by fluorescence-activated cell sorting (FACS) analysis. These results provided the basis for phase I clinical protocols to determine the expression and toxicity associated with retroviral-mediated transfer of the MDRl gene to hematopoi- etic cells in patients undergoing high-dose chemotherapy and autologous BM tran~plantation.'.~ Nonetheless, we sought to develop a rapid preclinical in vivo model to study gene transfer into human hematopoietic progenitor cells using nonobese diabetic severe combined immunodeficient mice (NOD SCID). This model would allow us to extend the current observations and determine the following: (1) whether other drug resistance genes (ie, dihydrofolate reductase) alone or in combination with MDRl can confer broader chemoprotection, (2) whether MDRl can be used to enrich for cells in vivo that coexpress other therapeutic genes (ie, glucocerebrosidase), and (3) establish methodology to examine normal hematopoietic cells in vivo to improve the efficiency of retroviral gene transfer into stem cells and to determine whether stem cell exhaustion could result from selection of stem cells in vivo. The studies reported here show for the first time that a human progenitor cell line transduced with an MDRl -containing retrovirus is resistant to the cytotoxic effect of paclitaxel in vivo.
MATERIALS AND METHODS
Cells. Growth factor-dependent MO-7e cells"'." were cultured in RPM1 1640 (GIBCO-BRL, Gaithersburg, MD) containing L-glutamine, penicillin, and streptomycin, 10% fetal calf serum (Atlanta Biologicals, Norcross, GA) and 30 pg/mL each of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) (Peprotech, Rocky Hill, NJ) (complete medium). Cell lines infected with the MDR1-containing retrovirus were maintained in complete medium supplemented with 10 ng/mL colchicine (GIBCO-BRL) unless specified otherwise.
Production of replication-defective arnphotrophic retrovirus containing the MDRI cDNA. The plasmid pHaMDRl/A" containing the MDRl cDNA in a retroviral vector derived from the murine Harvey sarcoma virus was a gift from Dr Michael Gottesman (National Cancer Institute [NCI], Bethesda, MD). The amphotrophic packaging cell line GP+env Am12" was a gift of Dr Arthur Bank (Columbia University, New York, NY). GP+env AM12 cells were transfected with pHaMDRI/A by calcium phosphate precipitation. Forty-eight hours after transfection, the packaging cells were selected in medium containing 20 ng/mL colchicine (GIBCO-BRL). Producer cell lines were grown to subconfluence, fresh nonselective medium was added, and viral supernatants were obtained 24 hours later. Supernatants were centrifuged at 3,000 rpm for 5 minutes to remove cell debris and titred to identify clones producing greater than S X IO4 infectious viral particles/mL. Virus containing supernatents were titered by serial dilution on NIH3T3 cells followed by selection in colchicine (40 ng/mL), and surviving colonies were scored 3 weeks later. Supernatants were used to infect MO-7e cells.
FACS. Parental MO-7e and MO-7e cells infected with MDRl -containing retrovirus were analyzed for the expression of the MDRl gene product, gp 170, by FACS analysis. Briefly, 1 X 10' cells were incubated with "-16 monoclonal antibodie~'~ in phosphate-buffered saline (PBS) containing I% bovine serum albumin (BSA) and 0. I % sodium azide for 30 minutes at 4"C, washed two times and then incubated with fluorescein isothiocyanate-labeled goat-antimouse IgG for 30 minutes at 4°C. Cells were washed two times in staining buffer and then fixed with staining buffer containing 2% paraformaldehyde. Cells were analyzed by FACS on a Coulter Profile (Hialeah, FL).
Proliferation assay. MO-7e cells were plated in 96-well plates (Costar, Cambridge, MA) at 1 x 10' cells per well in 100 pL of complete medium. Paclitaxel (Bristol Myers Squibb, Princeton, NJ) was diluted in the wells as indicated and cells were incubated for a total of 72 hours at 37°C. Then, I pCi of 'H-thymidine (6.7 Ci/ mmol) (New England Nuclear, Boston, MA) was added to each well 6 hours before the cells were obtained with an automated cell harvester (Tomtec cell-harvester; Wallac, Gaithersburg, MD) and counted by liquid scintillation.
Southern blot analysis. Genomic DNA was extracted from cell lines according to the procedures provided by the manufacturer (DNA extraction kit; Stratagene, La Jolla, CA). Twenty micrograms of DNA was digested with EcoRI (New England Biolabs, Beverly, MA), and then separated by gel electrophoresis. The quality of the digest and equal loading was confirmed by UV fluorescence of the ethidium bromide-stained gels. After depurination, denaturing, and neutralization steps, the DNA was transferred onto a Duralose-UV membrane (Stratagene) overnight in 20X standard citrate saline, and the transferred DNA was crosslinked using a Stratagene-UV crosslinker. The membranes were probed with an SacIIIXho I fragment (New England Biolabs) of pHah4DRI/A containing the fulllength MDRl cDNA labeled with 12P CY dCTP (3,000 Ci/mmol) (Amersham Life Sciences) by random prime labeling (Boehringcr Mannheim, Indianapolis, IN). Northern blot una1y.si.s. Total RNA was obtained from log phase growing cells using guanidine isothiocyanate cesium chloride purification." Poly A+ RNA was obtained from total RNA according to the procedures provided by the manufacturer (Poly-A Quik mRNA isolation kit; Stratagene). Ten micrograms of each sample was loadetl with I ' % ethidium bromide onto a l .O% agarose formaldehyde gel. The integrity of the RNA was veritied visually by ethidium bromide staining. The gels were blotted to Duralose-UV membrane according to the instructions provided by the manufacturer (Stratagene). The membranes were probed with MDRl cDNA as described above. To control for RNA loading, the blots were stripped with boiling H 2 0 and reprobed with "P-labeled 3GPDH (Clontech, Palo Alto, CA). Mice were irradiated with 350 cGy from a "'CS source and injected intravenously (IV) with 13 p g anti-asialo GM1 in 200 pL PBS to delete natural killer (NK) cells in vivo (Waco Chemicals, Richmond. VA) on the day preceding the transplantation. MO-7e parental clone S and MDR-infected clone 3-5 cells were resuspended at a concentration of 7 X IO' cells/mL in PBS/IOC/,' fetal calf serum with GM-CSF (Peprotech) and IL-3 (Peprotech), each at 100 ng/mL. and were injected intraperitoneally. Anti-asialo GM I injections were continued 011ce per week. After 4 weeks, mice were administered 12 mg/ kg paclitaxel intraperitoneally daily for a total of S days (60 mg/kg total dose). This dose was found to be the highest tolerated dose in our system (data not shown). After a 2-day rest period, mice were killed; femurs were harvested and BM cells were obtained.
Defenninarion of MO-7e rn,qrufrnzenf. DNA was extracted from BM cells of individual mice as described previously." One hundred nanograms of DNA was amplified by polymerase chain reaction (PCR) with @?-microglobulin primers. specific for human sequences (sense: S'CAG GTT TAC TCA CGT CAT CCA GC3' and antisense: S'TCA CAT GGT TCA CAC GGC AGG C 3 ' ) (Perkin Elmer Cetus. Branchburg, NJ). Amplification conditions were: 94°C X 2 minutes for one cycle followed by 94°C X I minute/66"C X 20 seconds/ 72°C X 20 seconds for 3 I cycles. One hundred nanograms of DNA of the same sample was also amplified using the same parameters f o r 24 cycles, using actin primers homologous with mouse and human sequences (sense: S'GTG ACG AGG CCC AGA GCA AGA G3' and antisense: S'ACG CAG CTC ATT GTA GAA GGT GTG G3'). Cycling conditions for both primer pairs were chosen to yield amplified product with the geometric range of the PCR reaction.The PCR products were loaded and separated on 8% polyacrylamide gels and then visualized with ethidium bromide staining. Equal amplification of hurnan and mouse sequences were demonstrated (data not hhown). The optical density of the bands specific for /?2-microglobulin ttnd actin (intensity of band density, IOD) were determined by scanning with an Omni Media Scanner (Bio Image System; Millipore. Ann Arbor, Ml). The optical densities of the @2-microglobulin bands were divided by the optical density of the corresponding actin band to correct for the total amount of DNA present in the sample. This ratio was then compared to a standard curve t o calculate the percentage of human DNA in the sample.
RESULTS
Production and characterization sf MO- Infected cells were then subcultured in medium containing IL-3, GM-CSF, and colchicine (20 ng/mL) to select for the transduced cells. The retroviral vector did not contain any additional drug selectable markers; therefore, the parental MO-7e cells served as the control cell line. As expected, the parental MO-7e cells were not viable after 48 to 72 hours in colchicine. Parental cells and the drug selected cells were subcloned by limiting dilution and used in subsequent experiments. Both the parental and MDRI-infected clones remained growth factor-dependent and were morphologically identical (data not shown). To demonstrate infection of MO7e cells with the MDRI-encoding retrovirus, genomic DNA was extracted from the cell lines for Southern analysis and probed with MDRI-specific sequences (Fig l ) . In parental clones (clones 5, 2-2, and 2) hybridization signals were seen at 19 kb, 10 kb, 5.8 kb, 2.5 kb, and 1.6 kb representing the endogenous MDR I genomic sequences. Infected MO-7e cells (clones 3-5,4-1, and 4-3) showed a 3.5-kb band (Fig 1,  arrow) representing hybridization of the probe to a restriction fragment wholly contained in the provirus. Other unique MDR 1 -specific bands representing cellular DNA provirus junction fragments were seen in the infected cell clones in addition to the endogenous bands present in parental clones (Fig I , arrows) . These findings were consistent with integration of the MDR l -containing retrovirus into MO-7e genomic DNA.
Parental Infected
To determine the level of transcription from integrated sequences derived from the viral construct, Northern blot analysis was performed (Fig 2) . Analysis on total RNA detected a signal at 9.0 kb in infected clones only (clone 4-1 and 4-3, both maintained under selection), which is the expected size of the RNA transcripts initiating from the HaMDR long terminal repeats. Furthermore, the signal could be seen at similar intensity in these two clones 6 months after removal of colchicine from the culture medium (Fig 2, Off Col. clone 4-1, Off Col. clone 4-3). Because MDRl mRNA was not detected in total RNA from uninfected cell clones (Fig 2, clones 5 and 2) and these cells showed low levels of MDRI expression by flow cytometry, we examined poly A RNA from the parental clones for MDRI expression. MDRl was not detected in the poly A RNA from two uninfected clones (Fig 2, Poly A To investigate the expression of the MDR-I gene product, cell-surface gp 170 was measured in parental and retrovirally infected clones by indirect immunofluorescence (Fig 3) . When compared with the isotype-matched controls (Fig 3A) , parental MO-7e cells were positive for gp 170 expression but showed low levels expression (Fig 3B) . In comparison, infected MO-7e cells selected in colchicine expressed much higher levels of gp 170 (12-fold increase in mean fluorescence intensity; Fig 3D) . Single-cell clones derived from parental or retrovirally infected MO-7e cells showed identical FACS results (data not shown). Furthermore, gp 170 could be demonstrated by Western blot analysis in transduced clones only, using the monoclonal antibody 4001 (gift of Dr Tito Fojo, NCI, Bethesda, MD, data not shown). Thus, parental MO-7e cell clones express low levels of MDRl protein that is greatly increased by infection with a retrovirus containing the MDRI gene.
To determine whether the expression of MDRI was stable in vitro, cells were cultured in vitro for 6 months in the absence of selection and then analyzed for MDRl expression by FACS. The percentage of MO-7e cells that were positive for MDRl was determined by setting the FACS gate for high expression of MDRI . Thus, because the parental MO7e cells express low levels of MDRI, using this gate, the parental clone was only 9% positive while the infected MO7e cells were 75% to 85% positive for high levels of MDRI expression (Fig 4) . The two MDRI-infected MO-7e clones (4-1 and 4-3) not kept under selective pressure showed high levels of MDRI expression over a 6-month culture period (54% and 7896, respectively). Although the expression of MDRl on clone 4-1 was decreased at the time examined, FACS analysis of clone 4-1 obtained 4 weeks later showed high levels of MDRl expression at 72%. Thus, expression of the transduced MDRl gene is stable in MO-7e cells and allows a potential use for these cells in vivo. Eflect qf pnclitnxel on MO-7e cell proliferation. To determine if increased expression of the MDR-l gene product in MO-7e correlated with an increased resistance to the cytotoxic effect of paclitaxel, cells were analyzed in 'H-thymidine incorporation assays. Paclitaxel inhibited the proliferation of MO-7e cells in a dose-dependent manner with a SO% inhibitory dose (IDs,)) of IO ng/mL, whereas in retrovirally infected cells the IDsCj for paclitaxel was 200 nglmL (Fig 5) . Further, both cell lines were not viable when maintained in paclitaxel concentrations that maximally inhibited 'H-thymidine incorporation (data not shown). Thus, resistance to Initial experiments to quantitate human cell engraftment in NOD SCID mice by FACS analysis with MRK-16, human lymphocyte antigens, or CD45 monoclonal antibodies showed a consistently high background fluorescence with isotype-matched control antibodies. Therefore, to determine the level of human cell engraftment in NOD SCID recipients, we developed a novel sensitive FCR protocol to detect human-specific DNA. First, MO-7e DNA and NOD SCID BM DNA were mixed at the following ratios: 1:2, 1:4, 1:8, 1: 16, 1:32, 1:64, 1:128, 1:256, and were amplified using actin (mouse and human DNA specific) or 02-microglobulin (human specific) sequences followed by scanning of band intensities according to the procedures described in Materials and Methods. To compensate for any loading differences, the optical densities of the 02-microglobulin bands (IOD 02-microglobulin) were divided by the optical density of the corresponding actin band (IOD actin). As expected, the intensity of the human P2-microglobulin specific PCR product (232 bp) decreased as the MO-7e DNA was diluted, while 2727 the intensity of the actin product (120 bp) remained constant (Fig 7) . A linear relationship was observed when the IOD (P2-microglobulin divided by actin) was plotted versus dilution of MO-7e DNA (Fig 8) . Therefore, similar standard curves were obtained in subsequent experiments to quantitate human MO-7e DNA in NOD SCID mouse BM DNA.
To determine the level of engraftment of MO-7e cells in NOD SCID mice, BM was obtained from transplanted mice, DNA was isolated, and PCR analysis performed as outlined above (Fig 9) . In addition, the optical densities of the separated ,B2-microglobulin and actin products from individual mice were determined as described in Materials and Methods. The IODs from the individual mice were averaged for each group and the percent human DNA in NOD SCID BM was derived from the IODs using a standard curve ( Table 1) . As expected, no human specific sequences were seen in ethidium bromide stained gels for the untransplanted NOD SCID animals (Fig  9, groups E and F) , whereas human-specific /32-microglobulin sequences were detected in MO-7e-transplanted and MDR1- Table 1 , group A and C, respectively). A significant ( P S .0077) decrease in human-specific DNA was observed in MO7e-bearing NOD SCID mice that were treated with paclitaxel (Fig 9 and Table 1 , group B). Specifically, in some animals, no human DNA was detected (Fig 9, group B: B!, B2, B5).
In comparison, all NOD SCID mice transplanted with MDR Iinfected MO-7e cells and treated with paclitaxel showed detectable human DNA sequences (Fig 9 and Table l, Table  l , compare group A with group C). Furthermore, sufficient engraftment occurred in both groups to develop a leukemia after 5 to 7 weeks. This leukemia coincided with a weekly increase in the percentage of human DNA in NOD SCID specific DNA in mixtures with mouse DNA. Different dilutions of human MO-7e cell DNA and 120 bpmouse BM DNA were amplified by PCR with human specific p2-microglobulin primers (232-bp fragment) and with actin primers that recognize mouse and human DNA (120-bp fragment) as outlined in Materials and Methods. Fig 6. Summary of transplantation protocol for NOD-SCID mice. Mice were irradiated with 350 cGy and injected with anti asialo GM1 the day before transplantation. MO-7e cells (7 x 10') were injected intraperitoneally (ipl. Paclitaxel treatment was initiated after 4 weeks and a total of 12 mglkg for 5 days was injected ip. BM cells from mice were obtained 2 days later. In both experiments 3 t o 9 mice in each group were available for harvest.
BM from 0% after I week, to less than I % after 2 weeks, to 10% to 15% after 4 weeks, and as high as 30% after 5 to 7 weeks or the time of death. Finally, the total BM cellularity for individual mice was determined and did not vary significantly between mice transplanted with parental MO7e cells or mice transplanted with MDRI-infected MO-7e cells (group A and group C) (data not shown). Paclitaxel treatment induced a significant decrease in total BM cellularity (approximately 50% on average) in mice transplanted with either cell line, such that no significant difference in cellularity was observed between groups B and D (data not shown). Taken together, human MO-7e cells expressing the transduced MDRl gene survive treatment with paclitaxel in vivo, whereas parental cells are decreased or eliminated.
DISCUSSION
Normal BM cells are particularly sensitive to chemotherapeutic agents in vivo, which results in neutropenia and thrombocytopenia and limits the maximum tolerated dose in cancer patients. Despite increased responses and even complete regression of malignancies in some cancer patients with dose intensification,"." the myelosuppressive effect of cytostatic therapy remains a major obstacle.'" Thus, protecting the BM from cytotoxic effects of cancer drugs would For personal use only. on October 31, 2017. by guest www.bloodjournal.org From * NOD SClD mice were transplanted with parental MO-7e cells or MO-7e cells transduced with the MDRl gene as summarized in Fig 6. t The optical density of PCR products was determined as described in Materials and Methods from harvested bone marrow for individual mice. The optical density of the 8-2 microglobulin band was divided by the optical density of the actin band to yield the IOD (p-2 microglobulin/ actin). IODs were pooled for the different experimental groups and the mean values are presented with the standard error.
*The percent of human DNA in total NOD SClD bone marrow was determined from a standard curve presented in Fig 8. § A paired Student's t-test was performed to determine if engraftment differed significantly between experimental groups.
--11 Denote significant differences ( P < .02).
factors are species specific, their survival and growth in NOD SCID mice must be supported by conditions yet undefined. It was not possible to determine the level of human cell engraftment in NOD SCID mice by FACS analysis because the fluorescence of isotype matched controls gave a high background. Using NOD SCID BM cells we were unable to decrease the background flourescence with antibodies that block Fc binding or human serum, which suggests that NOD SCID BM cells have a high autoflorescence. Therefore, we developed a sensitive PCR method to quantitate human cell engraftment. This method permits quantitation of the percentage of MO-7e cells engrafting the BM of NOD SCID mice by comparing the total amount of DNA in each sample to the amount of human MO-7e DNA. Specifically, to control for the total amount of DNA present, primers for actin that yield equivalent amounts of amplified product from either human or mouse DNA were used. The contribution of human DNA to the total DNA in each sample was evaluated by PCR using primers specific for human 02-microglobulin. Using a standard curve (Fig 8) generated by mixing known amounts of MO-7e DNA with NOD SCID BM DNA, we were able to quantitate the percentage of human engraftment in NOD SCID mice using the ratio of amplified product generated by PCR by the two primer sets. Thus, the percent engraftment obtained from the optical density of the PCR product of the human specific sequences is an accurate reflection of the total number of MO-7e cells in NOD SCID BM.
Although previous studies have shown that retroviral gene transfer of the MDRl gene to normal human BM progenitors results in functional gene expression and increased resistance to paclitaxel in vitro, the studies presented here extend these observations to an in vivo setting and show that (1) manipulated human hematopoietic progentor-like cells maintain a stable MDR phenotype after transplantation to the hematopoeitic microenvironment in vivo, (2) MDR-infected MO7e cells are protected from paclitaxel and survive in the hematopoietic microenvirnonment after chemotherapy, since chemotherapy can either have direct effects on the transplanted cells and/or effects on the cells that constitute the hematopoietic microenvironment that supports hematopoiesis and, ( 3 ) because the pharmacokinetics of paclitaxel in vivo are poorly understood: ' progenitor protection shows that the drug and its metabolites remain therapeutic in vivo. Taken together, the human-SCID chimera will serve as a preclinical model to assess the therapuetic index for chemotherapeutic agents.
Protocols in cancer patients are presently examining the toxicity and feasibility of retroviral-mediated MDRl gene transfer to human BM cells in cancer patients.'.' By definition, a phase one clinical trial has a toxicity endpoint. The question of a therapeutic or a chemoprotective effect is not addressed in the study design; however, similar to the observation in the murine models, enrichment of MDR1-expressing progenitor cells may occur in patients receiving repeated cycles of ~hemotherapy.~,' In this context, the NOD SCID model is a rapid and reproducible preclinical approach that will allow us to determine first, whether other drug-resistance genes such as dihydrofolate reductase, alone or in combination with MDR1, can confer broader chemoprotection to MO-7e cells or normal BM cells, and second, broader implications to provide an in vivo model to examine MDRl modulators to overcome drug resistance in leukemias. Taken together, these results provide us a framework that will allow us to extend this model to examine, in vivo, the optimal conditions to transfer the MDRl gene into normal hematopoietic progenitor cells. In addition, these studies further support a rationale for conducting clinical trials where dose intensification of MDRl -dependent drugs could result in improved response and survival in cancer patients. For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
